Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study-Reference-Cited by-同舟云学术

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

Published:2023-10-20 Issue:6 Volume:12 Page:2177-2193
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Meca-Lallana José E.,Prieto González José M.,Caminero Rodríguez Ana B.,Olascoaga Urtaza Javier,Alonso Ana M.,Durán Ferreras Eduardo,Espinosa Raúl,Dotor Julio,Romera Mercedes,Ares Luque Adrián,Pérez Ruiz Domingo,Calles Carmen,Hernández Miguel A.,Hervás García Miguel,Mendoza Rodríguez Amelia,Berdei Montero Yasmina,Téllez Nieves,Herrera Varó Nicolás,Sotoca Javier,Presas-Rodríguez Silvia,Querol Gutierrez Luis A.,Hervás Pujol Mariona,Batlle Nadal Jordi,Martín Ozaeta Gisela,Gubieras Lillo Laura,Martínez Yélamos Sergio,Ramió-Torrentà Lluís,Mallada Frechin Javier,Belenguer Benavides Antonio,Gascón-Giménez Francisco,Casanova Bonaventura,Landete Pascual Lamberto,Berenguer Leticia,Navarro Laura,Gómez Gutierrez Montserrat,Durán Carmen,Rodríguez Regal Ana,Álvarez Elena,García-Estévez Daniel A.,López Real Ana M.,Llaneza González Miguel A.,Marzo Sola María E.,Sánchez-Menoyo José L.,Oterino Agustín,Villaverde González Ramón,Castillo-Triviño Tamara,Álvarez de Arcaya Amaya,Llarena Cristina

Funder

Sanofi España

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00557-7.pdf

Reference31 articles.

1. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303.

2. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–56.

3. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705–16.

4. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O’Connor PW. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 85 years. Mult Scler. 2012;18(9):1278–89.

5. Freedman MS, Bar-Or A, Benamor M, Truffinet P, Poole EM. Long-term disability outcomes in patients treated with teriflunomide for up to 14 years: group-and patient-level data from the phase 2 extension study. Mult Scler J. 2017;23(3):637–8.